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Human Coronaviruses were discovered in the 1960s and were found to be a cause 
of the common cold, inducing mild symptoms on those infected (Santacroce et al., 2020). 
However, due to adaptation and co-evolution, more dangerous variations of 
Coronaviruses emerged in the early 2000s, causing severe infection of the respiratory 
tract (Ye et al., 2020). Notably, the outbreaks of severe acute respiratory syndrome 
(SARS) and Middle East respiratory syndrome (MERS) were devastating, as these 
HCoVs could inflict respiratory disease that can be fatal (Wong et al., 2016). Most 
recently, the emergence of a new strain of Human Coronavirus has taken the world by 
storm. SARS-CoV-2 was discovered in December of 2019 in Wuhan, China, and is 
responsible for the current global outbreak of the Coronavirus Disease 2019 or COVID-
19 (Santacroce et al., 2020). The World Health Organization has declared SARS-CoV-2 
as a worldwide public health threat due to its high rate of transmissibility, pathogenicity, 
morbidity, and mortality (Ye et al.,2020). As of May 20th, 2021, there has been a total of 
35,855,010 confirmed cases and 584,975 deaths in the United States alone (Centers for 
Disease Control and Prevention (CDC), 2021).  
The most notable and commonly known symptoms experienced by COVID-19 
patients all pertain to respiratory complications, including cough, shortness of breath or 
difficulty breathing, congestion, and fever (Mao and Jin, 2020). However, recently, there 
has been growing evidence that SARS-CoV-2 not only ambushes the respiratory system 
but also may invade the central nervous system (CNS) and give rise to neurological 
complications (Mao and Jin, 2020). Examples of neurological manifestations that have 




stroke, impairment of consciousness, seizure, and encephalopathy (Zubair et al., 2020). 
Currently, scientists are most concerned with investigating the neuropathology of SARS-
CoV-2, along with both the acute phase and long-term neurological implications (Cheng 
et al., 2020). This capstone project is a literature review of Human Coronaviruses, 
specifically SARS-CoV-2, and the current exploration of its relationship with the nervous 
system. Additionally, this capstone will highlight the present hypotheses postulated by 
researchers regarding the neuroinvasive and neuroinflammatory events that may lead to 






Introduction to Coronaviruses (CoVs) 
Coronaviruses (CoVs) are members of the family Coronaviridae, consisting of a 
group of RNA viruses that are enveloped, single-stranded, and positive-sense (Ye et al., 
2020). This particular family of viruses contains the largest known genome compared to 
other RNA viruses, with its size of approximately 26-32 kilobases (Su et al., 2016). CoVs 
received their designation due to their crown-like morphology, spike proteins that project 
from the virus membrane, which is visible under electron microscopy (Su et al., 2016).  
All Coronaviruses share a similarly organized genome that is non-segmented. One 
portion of the CoV genome includes two large overlapping reading frames, ORF1a and 
ORF1b, which encode the 16 nonstructural proteins, nsp1-nsp16, at the 5’ end (Ye et al., 
2020). The remaining section of the genome includes additional ORFs, which encode for 
the structural proteins spike (S), envelope (E), membrane (M), and nucleocapsid (N) at 
the 3’ end. Along with this, the different derivations of CoVs encode for distinct 
accessory proteins, specific to their lineages (Su et al., 2016). 
The Coronaviruses are classified into four genera predicated on their varying 
protein sequences: alpha-CoV, beta-CoV, gamma-CoV, and delta-CoV (Ye et al., 2020). 
The predominant gene source for alpha-CoVs and beta-CoVs are bats and rodents, while 
for gamma-CoVs and delta-CoVs, birds are the origin. The beta-CoV genera have been 
identified as containing most human Coronaviruses (HCoVs) and subdivided into four 
lineages, A, B, C, and D (Ye et al., 2020). Currently, there are seven known HCoVs. 




HCoV-OC43, HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-
CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2, 
are beta-CoVs (Ye et al., 2020). Most HCoVs typically result in minor symptoms, such as 
the common cold or diarrhea, since they primarily infect the upper respiratory tract and 
the gastrointestinal tract (Su et al., 2016). However, in contrast, it has been established 
that SARS-CoV, MERS-CoV, and SARS-CoV-2 are highly pathogenic and cause severe 
distress to the lower respiratory tract. Additionally, these CoVs are associated with a 
higher incidence of pneumonia, acute respiratory distress syndrome (ARDS), kidney 
failure, and death (Santacroce et al., 2020).  
Structure and Properties of Coronaviruses  
 Coronaviruses are spherical shaped and approximately about 125 nm in diameter 
(Malik 2020). As mentioned previously, CoV’s contain various structural proteins that 
contribute enormously to its function.  
Essential to recognize in the Coronavirus’ structure is the only protein located 
inside the core of the virus, the Nucleocapsid (N) protein. The N-protein contains an N-
terminal domain and a C-terminal domain, both of which have the capability to bind 
directly and optimally to the RNA (Fehr & Perlman, 2015). The N-protein is also highly 
phosphorylated, instigating a structural modification to the protein that augments its 
affinity to the viral RNA (Fehr & Perlman, 2015). Functionally, the N-protein serves to 
protect the viral RNA genome. In addition to this protective role, the N-protein is also 
vital in CoVs replication and transmission. The other structural proteins characteristic of 




Coronaviruses' most notable structural feature is the Spike (S) proteins, located on 
the outer surface of the virus. The S-protein is a Class I fusion protein, trimeric, heavily 
glycosylated, and contains the Receptor Binding Domain (RBD) (Kirtipal et al., 2020). 
The RBD has been classified as the most variable structure in Coronaviruses. The S-
protein functions to promote viral entry into the host cell through fusion by facilitating 
the attachment of the virus to the host cell receptors (Boopathi et al., 2020). In most 
CoVs, the S protein is cleaved by a host-cell protease, separating the protein into two 
distinct polypeptides, S1 and S2 (Fehr & Perlman, 2015). S1 is more prominent and 
comprises the RBD, while S2 becomes the stalk of the spike (Fehr & Perlman, 2015).  
The Envelope or E-protein is a small transmembrane protein and is sparse in 
quantity in the virus. Despite the limited amount, the E-protein has critical tasks. The E-
protein facilitates the assembly and release of the virus by affecting membrane 
permeability (Boopathi et al., 2020). In addition to this, the coronavirus E proteins 
contain an N-terminal ectodomain and a C-terminal endodomain that has an ion channel 
that contributes to the virus function depending on the particular type of coronavirus. For 
example, as Fehr & Perlman (2015) noted, SARS-CoV E protein is not needed for viral 
replication, but it is essential for pathogenesis. Furthermore, E protein is imperative in 
virus production and maturation, as it has been identified that recombinant CoVs without 
E protein are less virulent (Malik 2020).  
The Membrane (M) protein is the most abundant structural protein and defines the 
shape of the viral envelope (Malik 2020). The M protein has three transmembrane 
domains, featuring a small N-terminal glycosylated ectodomain and a larger C-terminal 




research on M proteins suggests that it exists as a dimer in the viral particle and has the 
ability to change conformations. The capacity to alter conformations allows the M protein 
to promote membrane curvature and bind to the nucleocapsid (Malik 2020). The M 
protein also has critical interactions with other CoV structural proteins. The relationship 
between the M protein and the S protein is required for retention of the S protein in the 
ER-Golgi intermediate compartment and creating new virions (Malik 2020). 
Additionally, it is imperative for the M protein to bind to the N protein in order to 
stabilize the nucleocapsid and internal core of the virus. The interactivity between the M 
and N proteins facilitates the packaging of the genome and release into viral particles 
(Fehr & Perlman, 2015).  
An additional structural protein has also been identified in a particular group of 
Coronaviruses, beta-CoVs. Hemagglutinin-esterase (HE) is a dimer located on the surface 
of the Virion (Boopathi et al., 2020). HE has a dual function of binding sialic acids on the 
surface of glycoproteins and acting as an acetyl-esterase. These activities have been 
considered to strengthen S protein-mediated cell entry and infection of the host cell (Fehr 
& Perlman, 2015). However, HE is not required for virus replication (Boopathi et al., 







Figure 1. Structure of a Coronavirus 
 
Origin and Transmission of SARS-CoV-2 
 SARS-CoV-2 is highly pathogenic and the third coronavirus in the past two 
decades to globally induce severe disease in humans (Wiersinga et al., 2020). Due to their 
ability to rapidly undergo genetic recombination and variation, Coronaviruses can adapt 
and infect a wide variety of hosts (Wiersinga et al., 2020). Examples of these hosts 
include birds and mammals, such as pigs, cows, chickens, dogs, and cats. However, bats 
are considered the major evolutionary and ecological reservoir for SARS-CoV-2 
(Umakanthan et al., 2020). The food market in Wuhan, China that sold live animals, most 
notably bats, was identified as the zoonotic source for the Coronavirus outbreak. Despite 
bats being the most promising reservoir for SARS-CoV-2, researchers speculate that 
humans were infected with the virus via an intermediate host, particularly the pangolin or 




 Human-to-human transmission of SARS-CoV-2 primarily occurs through 
respiratory droplets. These droplets can be excreted and inhaled by coughing, talking, or 
sneezing during face-to-face contact (Umakanthan et al., 2020). SARS-CoV-2 can also be 
transmitted through direct contact with a contaminated surface, aerosols (tiny droplets 
suspended in the air), and the fecal-oral route (Harison et al., 2020). Generally, contact 
with oral, nasal, and eye mucous membranes results in the spread of the COVID-19 virus 
(Umakanthan et al., 2020). High risk of transmission is characterized by prolonged 
exposure to an infected person or within 6 feet of the infected for at least 15 minutes 
(Wiersinga et al., 2020).  
Symptoms of the COVID-19 Infection 
 The potential symptoms of COVID-19 due to SARS-CoV-2 infection are non-
specific, and presentation varies. The clinical manifestations of SARS-CoV-2 are 
classified as either asymptomatic, mild, moderate, severe, or critical. The three most 
common symptoms are fever, cough, and shortness of breath. Other symptoms include 
myalgia (fatigue), weakness, nausea, diarrhea, vomiting, and changes in taste or smell 
(Wiersinga et al., 2020). Asymptomatic COVID-19 patients are characterized by not 
experiencing any clinical symptoms, chest imaging appearing normal, and still having a 
positive COVID nucleic acid test (Yuki et al., 2020). Mild cases of COVID-19 are 
denoted by symptoms of an upper respiratory tract infection, which includes fever, 
fatigue, cough, congestion, or digestive symptoms, which are nausea, vomiting, diarrhea, 
or general abdominal pain. Moderate COVID-19 disease is distinguished by experiencing 
pneumonia with frequent fever, cough, and no obvious hypoxemia. Chest CT in moderate 




with hypoxemia, or when SpO2 saturation is less than 92%. Finally, critical classification 
of COVID-19 is characterized by acute respiratory distress syndrome (ARDS), shock, 
encephalopathy, myocardial injury, heart failure, acute kidney injury, and coagulation 
dysfunction (Yuki et al., 2020).  
 Adverse reactions or outcomes to COVID-19 are primarily associated with 
increasing age or other underlying comorbidities. Other comorbidities include 
hypertension, diabetes, cardiovascular disease, and lung disease (Yuki et al., 2020).  
Mechanism of SARS-CoV-2 into Host Cells 
 Once SARS-CoV-2 enters the host through the respiratory tract, the potential 
severity of the disease that can ensue depends on the susceptibility and permissiveness of 
the host cells or immune system (Harrison et al., 2020). The life cycle of SARS-CoV-2 in 
the host cell consists of 5 steps: attachment, penetration, biosynthesis, maturation, and 
release (Santacroce et al., 2020). Attachment begins when the virus binds to the host 
cells’ receptors. Penetration occurs when the virus enters the cell either through 
endocytosis or membrane fusion. Replication transpires when the viral contents are 
delivered to the inside of the host cell, and the viral mRNA can enter into the nucleus. 
The viral mRNA is also used for biosynthesis or the production of viral proteins. Once 
the new viral proteins are constructed during maturation, they are released in the final 
step of the life cycle (Yuki et al., 2020).  
Attachment and penetration are primarily mediated through the actions of the S 
protein. The interaction between the S protein and the host cell receptor is the principal 




viral tissue tropism (Malik 2020). The S protein is a trimeric class I fusion protein that is 
densely glycosylated. As mentioned previously, the S protein contains two functional 
subunits. The first, S1, is the receptor-binding domain, and the second, S2, is responsible 
for the fusion of the viral and host cell membranes (Yuki et al., 2020). The binding of the 
S1 subunit to the host cell receptor is the instigating event for the fusion process of the 
viral membrane to the host cell membrane (Kirtipal et al., 2020).  
The central receptor identified as SARS-CoV-2’s primary entry point into host 
cells and aid in viral propagation is angiotensin conversion enzyme 2, or ACE2. ACE2 is 
a monocarboxypeptidase that interacts with many substrates in the human body, ranging 
from molecules in the renin-angiotensin system to molecules that aid in regulating blood 
sugar and insulin sensitivity (Santacroce et al., 2020). There are two different 
configurations of ACE2, the full-length form, and soluble form. The full-length form of 
ACE2 includes a transmembrane domain that has the ability to attach its extracellular 
domain to the plasma membrane (Santacroce et al., 2020). This functional variation of 
ACE2 is significant for the entry of SARS-CoV-2 into host cells, as the extracellular 
domain on ACE2 serves as a receptor for SARS-CoV-2. The soluble form of ACE2 is 
available in small quantities and circulates in the blood. Notable of the soluble form of 
ACE2 is that it lacks the membrane anchorage compared to its other structural 
counterpart (Santacroce et al., 2020).  
It is proposed that the strong affinity SARS-CoV-2 has to ACE2 is due to the 
virus’s S protein. The S protein binds to the ACE2 receptor, which results in a 2-step 
sequential protease cleavage cascade that eventually promotes viral uptake. Type 2 




enzyme that has been identified as being the primary protease responsible for cleaving 
the S protein and thus activating it (Morris et al., 2020). Additionally, scientists have also 
determined a possible alternative spike cleavage protease in cells that may express the 
ACE2 receptor but lack TMPRSS2, as cathepsin (Morris et al., 2020). The fusion of the S 
protein to the ACE2 receptor triggers TMPRSS2 to cleave and activate the S protein, 
which mediates coronavirus entry into host cells (Wiersinga et al., 2020). Although the 
protease cleavage mechanism for SARS-CoV-2 is not precisely understood, researchers 
have been following a model instituted by other highly pathogenic Coronaviruses that 
share similar characteristics, SARS-CoV and MERS-CoV. This model consists of 
protease cleavage at the S1/S2 site on the S protein for priming and cleavage at the S2 
site, located within the S2 subunit, adjacent to a fusion peptide (Yuki et al., 2020). 
Following the cleavage at the S1/S2 site, the S1 and S2 subunits stay non-covalently 
bound. The S1 subunit stabilizes the S2 subunit that is membrane-anchored at the 
prefusion state (Yuki et al., 2020). The second cleavage step at the S2 site is seemingly 
the event that activates the S protein for membrane fusion through irreversible 
conformational changes (Yuki et al., 2020). In addition to this, a characteristic unique 
only to SARS-CoV-2 is that its spike protein also contains a unique furin cleavage site at 
the S1/S2 junction. This specific cleavage site contributes to the virus pathogenicity by 
allowing other cellular polyprotein convertases, such as furin and capthesin, to cleave and 
activate the S protein, which enhances Coronavirus entry utilizing endocytosis (Morris et 
al., 2020).  
Alveolar epithelial cells, vascular endothelial cells, and alveolar macrophages are 




2020). This targeting is attributable to the fact that these cells express a significant 
amount of ACE2. Generally, the nasopharyngeal and oropharyngeal tissues contain a 
substantial amount of ACE2. Specifically, in the respiratory tract, the ACE2 receptor is 
broadly expressed on epithelial cells of the trachea, bronchi, serous bronchial glands, 
alveoli, alveolar monocytes, and alveolar macrophages (Kirtipal et al., 2020). Due to this 
and the high-affinity SARS-CoV-2 has for ACE2, the virus is able to efficiently infect the 
upper respiratory system (URT), accounting for some of the most devastating symptoms 
of COVID-19. Most notably, ACE2 and TMPRSS2 are highly expressed by alveolar 
epithelial type II cells (pneumocytes), making lung tissue the primary viral tropism for 
SARS-CoV-2 (Harrison et al., 2020). ACE2 expression has also been identified in other 
tissues, including the esophagus, ileum, colon, kidney (proximal convoluted tubules), 
myocardium, and bladder tissue (Umakannthan et al., 2020). Additionally, it has been 
determined that ACE2 is diffusely expressed on immune cells and cerebral neurons 
(Kirtipal et al., 2020).  
Host Response to SARS-CoV-2  
 Upon binding to host epithelial cells in the respiratory tract, SARS-CoV-2 begins 
the initial stages of infection by replicating and migrating down the airway, entering the 
alveolar epithelial cells in the lungs (Hu et al., 2020). As a result, the immune system 
begins to respond due to the rapid viral replication. The three components for innate 
immunity, specifically in the airway, are epithelial cells, alveolar macrophages, and 
dendritic cells (Yuki et al., 2020). The dendritic cells and macrophages begin to combat 




 The role of T cell-mediated response to SARS-CoV-2 is still being investigated. 
However, scientists have used the identified adaptive immune response in SARS-CoV, 
the Coronavirus most similar to SARS-CoV-2, to make inferences on the possible 
mechanism. Antigen-presenting cells (APCs), such as dendritic cells and macrophages, 
initiate a T cell response either when they phagocytize apoptotic cells infected by the 
virus or are primarily infected by the virus (Yuki et al., 2020). It has been determined that 
SARS-CoV can bind to dendritic-cell specific intercellular adhesion molecule-3-grabbing 
nonintegrin (DC-SIGN), which is highly expressed on dendritic cells and macrophages. 
There is speculation that SARS-CoV-2 also shares this ability, which allows the virus to 
directly infect dendritic cells and alveolar macrophages (Yuki et al., 2020). As part of the 
immune response, these APCs migrate to the lymph nodes to present the viral antigen to 
the T cells. CD4+ T cells and CD8+ play an integral role in eradicating the virus by 
promoting the activation of B cells to generate virus-specific antibodies and directly 
killing infected cells, respectively (Yuki et al., 2020). However, research has observed 
that SARS-CoV-2 can escape the control of the immune system and, as a result, disrupt 
its normal function. 
 Studies have indicated that patients infected with SARS-CoV-2 presented with 
lymphopenia, or the decrease in the number of lymphocytes, to prevent the elimination of 
the virus (Santacroce et al., 2020). According to Morris et al. (2020), drastically reduced 
CD4+ T cells, CD8+ T cells, B cells, and natural killer cells are a characteristic feature of 
the COVID-19 disease. Additionally, there is accumulating evidence that patients 
infected by the virus experience excessive systemic immune activation and inflammation, 




severe COVID-19 disease had increased plasma concentrations of pro-inflammatory 
cytokines, such as interleukin (IL)-6, IL-2, IL-7, IL-10, granulocyte-colony stimulating 
factor (G-CSF), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory 
protein (MIP)1, and tumor necrosis factor (TNF)- (Rothan et al., 2020). It has been 
observed that this inflammatory effect can cause acute damage to the lung tissue and lead 
to acute respiratory distress syndrome (Santacroce et al., 2020). Numerous autopsy 
reports of patients with severe COVID-19 primarily included histological examination of 
lungs, which commonly revealed bilateral diffuse alveolar damage, hyaline membrane 
formation, desquamated type II pneumocytes, and fibrin deposits (Hu et al., 2020). 
Finally, reports of thrombosis and pulmonary embolism have been noted in severe 
COVID-19 cases. These findings are attributable to the fact that SARS-CoV-2 causes the 
hazardous activation of coagulation and consumption of clotting factors to occur 
(Wiersinga et al., 2020). SARS-CoV-2 inflicts severe endothelial injury, and the 
endothelium plays a vital role in thrombotic regulation (vasodilation, fibrinolysis, and 
anti-aggregation) (Yuki et al., 2020). Also, it is essential to note that endothelial cells 
express ACE2 (Yuki et al., 2020).    
SARS-CoV-2 and the Connection to the Nervous System  
 Although the primary manifestations of SARS-CoV-2 mainly involve pulmonary 
complications, there has been steadily increasing evidence that the virus also infects the 
central nervous system (CNS), causing neurologic dysfunction (Mao et al., 2020). The 
various neurological symptoms of COVID-19 that have been reported include 




(Bougakov et al., 2021). Also, the development of different neurological diseases or 
conditions has been accounted for due to COVID-19, such as encephalitis and Guillain-
Barré syndrome (Zhou et al., 2020). Neuropsychiatric symptoms are also an additional 
topic of interest for COVID-19. Not only have these symptoms come to rise in the 
population due to pandemic-associated psychological distress, but there may be 
psychological effects due to direct infection of the virus. There is concern for the acute 
phase and long-term neurological manifestations of SARS-CoV-2, as COVID-19 patients 
may be at increased risk for developing neurodegenerative diseases years later post-
infection or experiencing permanent cognitive impairment (Bougakov et al., 2021).  
   Although the exact mechanism through which SARS-CoV-2 invades the nervous 
system is still unknown, researchers have been proposing various hypotheses from 
available information on the virus, previous coronaviruses, and evidence from patients 
infected. Scientists have been speculating that the brain can both be directly and 
indirectly targeted by COVID-19. So far, four main potential neuroinvasive pathways 
have been identified for SARS-CoV-2. One involves direct infection of the CNS by 
neuronal pathways via retrograde transport along peripheral nerves (Yavrpour-Bali & 
Ghasemi-Kasman, 2020). A neuronal pathway specifically highlighted in SARS-CoV-2 
is axonal transport through the olfactory nerve, which is proposed to eventually infect the 
neuroanatomical structures that follow in that path (Bougakov et al., 2021). Another 
includes a hematogenous route, where SARS-CoV-2 enters the CNS by crossing the 
blood-brain barrier (BBB) (Cheng et al., 2020). Lastly, the two other identified courses of 
neuroinvasion are due to secondary hypoxia and immune injury (Wu et al., 2020). These 






Proposed Direct and Indirect Neurotropic Mechanisms of SARS-CoV-2  
 Neuronal Pathway  
  The main idea for this proposed mechanism is that SARS-CoV-2 can 
infect peripheral nerve terminals, move retrograde along the nerve synapses, and 
eventually gain access into the CNS (Zubair et al., 2020). Transcribrial and transsynaptic 
spread has been observed amongst several different Coronaviruses, both human and non-
human.  It is speculated that viruses migrate to the CNS and achieve retrograde neuronal 
transport by using motor proteins (Wu et al., 2020).  
 A prevalent symptom reported by COVID-19 patients is loss of taste (ageusia) 
and smell (anosmia). This clinical manifestation is strong evidence of SARS-CoV-2 
affecting cells in the CNS due to the unique anatomical organization of the olfactory 
system and the brain (Dempsey, 2020). The olfactory nerve essentially serves as a 
channel between the olfactory epithelium and the forebrain, where the virus can spread 
transcribrially (Wu et al., 2020). The proposed transsynaptic mechanisms in which the 
virus spreads retrogradely towards the CNS include an endocytosis/exocytosis transfer 
and a fast axonal transfer (FAT), where vesicle transport is used to pass the virus along 
microtubules back to neuronal cell bodies (Zubair et al., 2020). This is extremely 
problematic because it has been observed that SARS-CoV-2 can infect the brain and 
cerebrospinal fluid through the olfactory nerve and inflict inflammation and 




olfactory nerve is one of the main proposed neurotropic mechanisms for COVID-19. It is 
hypothesized that SARS-CoV-2 may penetrate the cribriform plate, which is located near 
the olfactory bulb and olfactory epithelium (Yavrpour-Bali & Ghasemi-Kasman, 2020). 
Moreover, SARS-CoV-2 may infect the olfactory receptor neurons in the olfactory 
epithelium using ACE2 or TMPRSS2 receptors (Yavrpour-Bali & Ghasemi-Kasman, 
2020). This results in SARS-CoV-2 uptake into the ciliated dendrites/soma, which then 
the virus can utilize retrograde transport along the olfactory nerve into the CNS 
(Yavrpour-Bali & Ghasemi-Kasman, 2020).  
 Research has shown that ACE2 and TMPRSS2 receptors are highly expressed in 
human and mouse olfactory mucosa (Meinhardt et al., 2020). This evidence is why 
researchers attribute the susceptibility of the olfactory tissue to SARS-CoV-2 and as a 
means of transportation to the CNS. In studies conducted with SARS-CoV, the “sister” 
virus to SARS-CoV-2, infected mice revealed pathology, determining that the virus 
appeared to enter the brain through the olfactory bulb and disseminated transneuronally 
to distally connected neurons (Cheng et al., 2020). In another study noted by Zubir et al. 
(2020), mice that had their olfactory neurons chemically ablated were protected from 
infection from HCoV-OCR43 invasion into the CNS. However, conflicting studies 
suggest only the olfactory epithelium expresses ACE2, not the olfactory neurons, 
implying that SARS-CoV-2 cannot penetrate the nerve cells (Zubair et al., 2020). Further 
studies using autopsy reports and murine models need to be conducted to provide further 
clarification.  
 In addition to this, it has been found that there is a potential for SARS-CoV-2 to 




numerous brain structures, including the brainstem, cortex, striatum, and hypothalamus 
(Bougakov et al., 2020). ACE2 has also been reported to be expressed on neurons and 
glial cells located throughout the brain. This is important as these structures and cells 
become potential targets for SARS-CoV-2 infection due to their expression of ACE2 
(Bougakov et al., 2020). Other receptors are also in the process of being identified as 
potential mediators for SARS-CoV-2 infection in the brain. One of the newly recognized 
receptors is CD147 or Basigin. It is currently being investigated for its role in the viral 
entry of SARS-CoV-2 into brain tissue and serving as another entry point for SARS-
CoV-2 (Bougakov et al., 2020).  
 Hematogenous Pathway 
  For this pathway, it has been identified that SARS-CoV-2 has the potential 
to enter the central nervous system (CNS) by entering the bloodstream. It is important to 
note that there has been evidence of this mechanism of entry into the CNS by other 
Coronaviruses, such as MERS-CoV and SARS-CoV (Reza-Zaldivar et al., 2020). 
Remarkably, the most common viral entry point into the CNS from the bloodstream is 
through the Blood-Brain Barrier (BBB) (Reza-Zaldivar et al., 2020). First, it has been 
proposed that SARS-CoV-2 can enter the bloodstream by infecting and damaging the 
epithelial cells. SARS-CoV-2 can likely injure the epithelium barrier and pervade the 
bloodstream (Lima et al., 2020). Specifically, the hypothesized origin of SARS-CoV-2 
infection into blood circulation is in the respiratory tract. As mentioned previously, type 
II pneumocytes are the population of cells that SARS-CoV-2 primarily infects, and they 
highly express ACE2. As a result, when these epithelial cells are infected, SARS-CoV-2 




proposed entryway for SARS-CoV-2 to enter the blood circulation is through the 
infection of the epithelial cells of the gastrointestinal (GI) tract (Lima et al., 2020).  
 Once SARS-CoV-2 has invaded the bloodstream, it has the potential to 
disseminate and infect the brain endothelial cells through the binding of ACE2, 
disrupting the BBB (Lima et al., 2020). Lima et al. (2020) described that the potential 
consequences of SARS-CoV-2 penetrating the BBB are edema, increased intracranial 
hypertension, and increased promotion of virus in the CNS. Paniz-Mondolfi et al. (2020) 
reported that a structural analysis revealed viral-like particles of SARS-CoV-2 were 
observed in the endothelial cells and pericytes of brain capillaries. In addition to this, the 
viral-like particles were also found in the astrocytic processes and contributing to the 
BBB dysfunction (Paniz-Mondolfi et al., 2020). In another recent study reported by 
Erickson et al. (2021), the S protein component of SARS-CoV-2 was found to induce 
BBB leakage in primary human in vitro BBB models. These studies suggest that the 
hematogenous pathway is a possible means of entry for the SARS-CoV-2 virus into the 
CNS.  
There is an additional proposed mechanism for SARS-CoV-2 to enter the CNS by 
the hematogenous pathway, by infection of the endothelial cells of the choroid plexus, 
therefore penetrating the blood-cerebrospinal fluid barrier (BCSFB) (Yachou et al., 
2020). This method of entry requires further investigation.  
Although the virus-mediated dysfunction of the BBB could potentially be in 
response to direct infection by SARS-CoV-2, other indirect responses instigated by the 




infection of endothelial cells (that overexpressed ACE2) generated the overexpression of 
clotting factors, adhesion molecules, and pro-inflammatory cytokines. This 
overexpression may be damaging to the BBB, causing it to be more permeable, and may 
promote viral entry into the CNS.  
 Immune Response and SARS-CoV-2 
  Both entry of SARS-CoV-2 into the CNS and nervous system damage 
may result from the immune system’s response. As a result of SARS-CoV-2 infection, 
the immune system instigates a systemic inflammatory response. This response involves 
overproducing pro-inflammatory cytokines, chemokines, and complement (Erickson et 
al., 2021). This overexpression and increased inflammation produced by the immune 
response can have various effects on the nervous system.  
First, the released factors can alter the permeability of the BBB (Yavarpour-Bali 
& Ghasemi-Kasman, 2020). Specifically, cytokines such as interleukin (IL)-1β, IL-6, 
Tumor Necrosis Factor (TNF)-α, and Interferon (IFN)- γ can disrupt the BBB by 
controlling transcytosis by adjusting the function of BBB transporters (Erickson et al., 
2021). In addition to this, according to Erickson et al. (2021), cytokines and chemokines 
TNF- α, IL-1α, IL-1β, IL-1RA, IL-6, CCL2, and CCL11 serve as substrates for transport 
across the BBB. When production of these elevates, there is increased transport across 
the BBB, thus allowing the opportunity for SARS-CoV-2 to invade the CNS.  
Next, it is postulated that the upregulation of the immune system in response to 
SARS-CoV-2 may result in inflammatory injury, leading to brain damage such as edema 




also been theorized that the overexpression of the immune system due to infection may 
instigate a cytokine storm, which results in a systemic inflammatory response and a 
critical cause of ARDS (Song et al., 2020). In short, the hyper-inflammation generated by 
SARS-CoV-2 infection can impair neurovascular endothelial function, dysregulate the 
BBB, and may be a significant contributor to the CNS clinical manifestations observed in 
patients with COVID-19 (Najjar et al., 2020).  
Finally, the last proposed mechanism of CNS damage inflicted by SARS-CoV-2 
through the immune system is peripheral immune transmigration, often referred to as the 
“Trojan Horse” mechanism (Lima et al., 2020). This mechanism requires infected 
immune cells, such as leukocytes, to travel into the brain. Currently, there is speculation 
that SARS-CoV-2 could inflect the peripheral bloodstream leukocytes, predominantly 
monocytes/macrophages, and myeloid cells (Lima et al., 2020). The infection of these 
cells would potentially facilitate dissemination to the CNS. SARS-CoV-2 would utilize 
these cells as vehicles to travel across the BBB, meninges, and choroid plexus into the 
CNS (Reza-Zaldivar et al., 2020). It is known that SARS-CoV utilizes this mechanism by 
infecting lymphocytes, monocytes, and macrophages, resulting in lymphopenia, a 
condition that has also been reported in SARS-CoV-2 infected individuals (Lima et al., 
2020). Based on this, as Lima et al. (2020) noted, researchers hypothesize that SARS-
CoV-2 utilizes circulating immune cells and dendritic cells to disperse into the CNS.  
 Hypoxia and SARS-CoV-2 
  Hypoxia is another process that occurs due to SARS-CoV-2 infection and 




which SARS-CoV-2 can inflict damage on the nervous system (Yavarpour-Bali & 
Ghasemi-Kasman, 2020). When the virus proliferates in the cells in the lung tissue, it can 
produce alveolar and interstitial inflammatory exudation and edema (Wu et al., 2020). 
This, in turn, can lead to dysfunction of alveolar gas exchange, which eventually results 
in hypoxia in the CNS (Yavarpour-Bali & Ghasemi-Kasman, 2020). In response to this 
hypoxia, brain cells begin rapidly undergoing anaerobic metabolism, leading to the 
accumulation of lactic acid (Wu et al., 2020). Following this, cerebral vasodilation, 
interstitial edema, cerebral blood supply obstruction, and headache due to ischemia may 
occur (Yavarpour-Bali & Ghasemi-Kasman, 2020). If the individual infected with SARS-
CoV-2 remains in a hypoxic state, brain function will continue to deteriorate as 
intracranial pressure increases and may result in coma or death (Wu et al., 2020). In 
addition to this, severe hypoxia may provoke acute cerebrovascular disease, such as an 
ischemic stroke (Wu et al., 2020). In essence, hypoxia-induced by SARS-CoV-2 
infection may cause damage to the nervous system.  
 
Neurological Conditions and Symptoms Associated with SARS-CoV-2 
 As more information continues to be discovered about SARS-CoV-2, there is 
increased evidence accumulating in support that the virus invades the CNS and inflicts 
neurological damage, as demonstrated by the clinical neurological manifestations. 
Various neurological complications have been reported in patients infected with SARS-
CoV-2. These conditions range in severity from mild such as headache, anosmia, and 




cerebrovascular complications, encephalopathy/encephalitis, seizures, Guillain-Barré 
Syndrome, delirium, and psychiatric disorders (Erickson et al., 2020).   
 Headache  
  Headache has been the most common neurological symptom reported by 
patients who have been infected by SARS-CoV-2 (Zhou et al., 2020). Not only this, but 
headache was also a chief complaint of COVID-19 in general, accompanying the more 
classic symptoms of fever, cough, and shortness of breath (Zubair et al., 2020). The 
prevalence of headaches in COVID-19 patients was reported to be as high as 70% (Al-
Ramadan et al., 2021). Although headache is an established indication of conditions such 
as meningitis, encephalitis, and intracranial hypertension, its relationship to the 
pathophysiology of SARS-CoV-2 is still unknown (Zubair et al., 2020). Some researchers 
postulate that the neuroinflammatory mechanisms that occur by cytokines and 
chemokines resulting from infection may contribute to the production of headaches 
(Zubair et al., 2020). However, it is currently understood by scientists that headache, 
along with the other neurologic manifestations of COVD-19, could potentially be 
attributed to direct infection of the virus, or secondary factors, such as the immune 
system (Erickson et al., 2020).  
 Anosmia and Ageusia  
  Al-Ramadan et al. (2021) reported that olfactory and gustatory impairment 
was a common neurological symptom of SARS-CoV-2 infection. Notably, anosmia and 
ageusia were reported as early manifestations of SARS-CoV-2, appearing in the first five 
days of illness (Zhou et al., 2020). As recognition of COVID-19 continued to improve 




from about 19.4% to 88% (Zhou et al., 2020). In a study with 417 participants diagnosed 
with mild to moderate COVID-19, scientists observed that the incidence of olfactory 
dysfunction was 85.6%, and gustatory dysfunction was 88% (Al-Ramadan et al., 2021). 
Notably, olfactory dysfunction was not associated with rhinitis or nasal dysfunction 
(Zubair et al., 2020) but was significantly linked to fever and gustatory symptoms (Al-
Ramadan et al., 2021).  
 Impaired Consciousness  
  In a study conducted by Mao et al. (2020), 37% of hospitalized patients 
due to COVID-19 experienced impaired consciousness. Researchers suggest that the 
underlying reasons behind hindered consciousness due to SARS-CoV-2 may be due to 
several aspects, including direct infection to the brain parenchyma, encephalopathy, or 
seizures (Zubair et al., 2020).   
 Infectious Toxic Encephalopathy  
  Encephalopathy is a non-specific term used to describe impairment in 
brain function (Al-Ramadan et al., 2021). Hallmarks of encephalopathy are altered 
mental status or impaired consciousness, confusion, headache, lethargy, delirium, or 
coma (Zubair et al., 2020). Infectious toxic encephalopathy, also known as acute toxic 
encephalitis, is a specific type in which reversible brain dysfunction is caused by the 
processes of acute infection (Wu et al., 2020). These processes include severe 
inflammation, hypoxia, viremia, and metabolic dysfunction (Wu et al., 2020). The 
significant pathological change in this condition is cerebral edema, with no evidence of 
inflammation present in the cerebrospinal fluid (Wu et al., 2020). Due to the proposed 




SARS-CoV-2 may potentially cause acute toxic encephalitis. However, more studies 
need to be conducted to investigate this relationship further.  
 Viral Encephalitis  
  Encephalitis is a severe condition that causes various neurological 
abnormalities, including headache, fever, convulsions, impaired consciousness, 
hallucination, confusion, aphasia, and impaired movement (Al-Ramadan et al., 2021). 
Wu et al. (2020) reported that encephalitis concerns the inflammatory lesions in the brain 
that cause neuronal damage generated by pathogens. Although some SARS-CoV-2 
associated encephalitis is now being reported, such as one involving a 41-year old 
diabetic woman diagnosed with COVID-19 and CSF analysis consistent with viral 
infection (Al-Ramadan et al., 2021), more research needs to be conducted on this 
association. 
Seizure 
  Seizures linked to SARS-CoV-2 infection have been reported in about 
10% of COVID-19 patients (Zubair et al., 2020). It is also important to note that seizures 
have been reported in other coronavirus infections. Additionally, Zubair et al. (2020) 
reported that patients who have a primary seizure disorder and contract COVID-19 are at 
a higher risk for seizure and status epilepticus. Al-Ramadan et al. (2021) stated that non-
epileptic seizures have also been described; however, further investigation into these 
cases is needed.  
 Cerebrovascular Complications  
  Occlusion or rupture of the blood vessels that comprise the 




stroke (Al-Ramadan et al., 2021). In addition to this, an ischemic brain injury that is 
induced by the inflammatory response due to SARS-CoV-2 may also cause an acute 
cerebrovascular complication (Wu et al., 2020). It has been found that patients with 
severe COVD-19 disease often present with elevated D-dimer levels and significantly 
decreased platelet reduction, which also may induce a cerebrovascular complication (Wu 
et al., 2020). Many cases are emerging reporting COVID-19 patients who experienced a 
stroke. It is important to note that most of these patients were: significantly older, had 
more cardiovascular risk factors, had higher levels of D-dimer and C-reactive protein, 
indicative of a hypercoagulative state (Zubair et al., 2020). However, a recent study in 
New York observed that COVID-19 patients younger than 50 years old also experienced 
large-vessel strokes (Zubair et al., 2020). Thus, more studies need to be conducted.  
 Guillain-Barré Syndrome 
  Guillain-Barré Syndrome or acute inflammatory demyelinating 
polyneuropathy (AIDP) is a condition that has been slowly emerging in patients with 
COVID-19. Guillain-Barré Syndrome is known to develop following a gastrointestinal or 
respiratory illness. The disorder, using a mimicry mechanism in order to bind to the 
peripheral nervous system, results in neuronal dysfunction (Zubair et al., 2020). A study 
reported 5 cases of Guillain-Barré Syndrome in Italy following a COVID-19 infection. In 
most cases, the patients presented with paresthesia and lower-extremity weakness (Zubair 
et al., 2020). Al-Ramadan et al. (2021) stated that another study potentially found 24 
cases of Guillain-Barré Syndrome associated with COVID-19. The emergence of these 
cases indicates Guillain-Barré Syndrome is a complication of COVID-19; however, more 




 Psychiatric Disorders  
  The COVID-19 pandemic in itself has served as a significant 
psychological stressor. Depression, anxiety, insomnia, and trauma-related disorders have 
been reported due to the SARS-CoV-2 pandemic. The current data conveys that the 
frequency and severity of psychiatric symptoms are associated with proximity to 
COVID-19 patients (Troyer et al., 2020). In addition to the psychological conditions 
people are experiencing due to the global pandemic, neurotropic mechanisms of SARS-
CoV-2 may promote the onset of psychiatric symptoms (Orsini et al., 2020). Researchers 
speculate the association between SARS-CoV-2 infection and psychiatric symptoms may 
be attributable to the systemic inflammatory response that occurs due to infection (Orsini 
et al., 2020). Common psychiatric conditions emerging are depression, delirium, and 
psychosis (Orsini et al., 2020). In order to fully comprehend the association between 
SARS-CoV-2 and psychological symptoms, more studies need to be conducted.  
 
RECOMMENDATIONS FOR FUTURE STUDIES 
SARS-CoV-2 infection and its proposed ability to invade the CNS only continue 
to grow in strength with the emerging evidence. As scientists continue to study the 
various mechanisms of SARS-CoV-2, there will be more definitive answers regarding 
how the virus functions and the damage it executes. Researchers across the globe have 
been working to gain insight into SARS-CoV-2’s neurotropic methods by using available 
information on previous coronaviruses and attempting to begin data collection. As 
research on COVID-19 continues, scientists can specifically test the proposed 




Understanding the mechanism through which SARS-CoV-2 can enter the CNS is 
imperative, as it will provide the information necessary to decipher why the specific 
neurological conditions are occurring. In addition to this, it is also crucial for scientists to 
continue investigating the neurological disorders associated with COVID-19 to assess the 
strength in their correlation. Studying and being cognizant of these severe neurological 
conditions may lead to early detection and better outcomes with severely ill patients. 
Finally, long-term assessments of COVID-19 patients are critical to understanding the 
chronic effects of this disease. 
 
RESEARCH STRATEGIES 
An in-depth analysis of multiple sources conducted in this review. To obtain 
sufficient information on the subject of Coronaviruses, numerous reputable databases 
were used, such as ScienceDirect, Google Scholar, MEDLINE, ResearchGate, PubMed 
Central, JSTOR, and the New England Journal of Medicine. In addition to searching for 
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